PROK
4:05 PM
ProKidney Reports Second Quarter 2026 Financial Results and Business Highlights
Completed enrollment of patients contributing to the Phase 3 PROACT 1 accelerated approval efficacy analysis, positioning the Company for anticipated pivotal eGFR slope topline results in Q2 2027 On track for completion of full enrollment for PROACT 1 in the second half of 2026 Appointed Kenneth
Enrollment • Phase 3Enrollment milestone Tue, Jun 30, 2026prokidney.com